Knee Osteoarthritis ClinicalTrial Near You

Knee osteoarthritis (OA) is a prevalent degenerative joint disease characterized by the progressive breakdown of articular cartilage, subchondral bone remodeling, and synovial inflammation, leading to pain, stiffness, and reduced mobility. Affecting over 250 million people worldwide, it is a leading cause of disability, particularly among older adults, with significant socioeconomic implications including healthcare costs exceeding $185 billion annually in the United States alone. Risk factors such as age, obesity, joint injury, and genetic predisposition exacerbate the condition, often resulting in diminished quality of life and increased reliance on assistive devices or surgical interventions like total knee arthroplasty.
Current management strategies for knee OA encompass a multimodal approach, including non-pharmacological interventions (e.g., physical therapy, weight management), pharmacological treatments (e.g., analgesics, nonsteroidal anti-inflammatory drugs), and intra-articular injections (e.g., corticosteroids, hyaluronic acid). However, these options frequently provide only symptomatic relief and are limited by side effects, variable efficacy, and the inability to halt disease progression. Emerging therapies, such as regenerative medicine approaches (e.g., platelet-rich plasma, stem cell therapy) and novel pharmacological agents targeting inflammatory pathways, hold promise but require rigorous evaluation to establish safety, efficacy, and long-term outcomes.
This clinical trial aims to investigate [insert specific intervention, e.g., a novel biologic therapy or exercise regimen] in patients with moderate-to-severe knee OA. By employing a randomized, double-blind, placebo-controlled design, the study seeks to assess improvements in pain scores, functional mobility, and joint health biomarkers over a 12-month period. The rationale stems from preclinical evidence suggesting [briefly describe mechanism, e.g., anti-inflammatory properties that modulate cartilage degradation]. Ultimately, this trial contributes to advancing evidence-based treatments, potentially offering a disease-modifying option that addresses the unmet needs in knee OA management and improves patient outcomes.